Feb 11, 2016 at 09:04 | Source: PTI
As per the government order last week, the Central Board of Excise and Customs has withdrawn exemption on as many as 74 drugs, including life savings drugs for treating cancer and HIV, from levy of customs duty.
Feb 10, 2016 at 16:18 | Source: PTI
Defending the move to end thecustoms duty exemption for import of 76 life saving drugsincluding those for treating cancer, AIDS and haemophilia,Government has said Indian manufacturers are already sellingmost of these drugs at cheaper prices.
Feb 08, 2016 at 08:53 | Source: PTI
The Mumbai-based company has included its two drugs -- Abirapro prescribed for prostate cancer and Evermil, indicated for different cancers, such as breast and renal cell carcinoma -- under the scheme. Currently, Abirapro 250 mg in 120 pack size is priced at Rs 39,990.
Feb 02, 2016 at 09:57 | Source: Moneycontrol.com
The company's subsidiary has received final approval for Imatinib Mesylate from Food and Drug Administration (FDA) in December 2015.
Jan 22, 2016 at 18:45 | Source: Reuters
India's federal drugs controller issued an alert on Thursday, asking states to ensure Swiss drugmaker Roche's cancer treatment Avastin was not administered to treat eyes, after its usage hampered vision in 15 patients.
Jan 22, 2016 at 08:19 | Source: Reuters
Despite being a cancer drug, Avastin is often used by doctors globally for eye ailments even though it does not have US Food and Drug Administration approval for that purpose.
Jan 20, 2016 at 10:25 | Source: Reuters
Avastin is a cancer drug but is often used by doctors to treat vision loss even though it has not been approved by the US Food and Drug Administration for that purpose. Studies have shown that eye injections of Avastin curb vision loss.
Jan 12, 2016 at 19:44 | Source: PTI
As part of its strategic priorities for the next decade, the Mumbai-based firm also wants to build leadership position in various therapeutic segments, including dermatology and cancer treatment drugs.
Jan 08, 2016 at 13:15 | Source: PTI
The novel clinical development candidate, GBR1342 is an antibody based on the company's proprietary BEAT platform, Glenmark Pharmaceuticals said in a regulatory filing. BEAT is Glenmark's technology for production of bi-specific antibodies.
Jan 05, 2016 at 11:18 | Source: Moneycontrol.com
"Glenmark reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine - Erlotinib Hydrochloride," says the Mumbai-based pharma company in its filing.